c-Myc tag Peptide: Precision Reagent for Immunoassays and Cancer Research

Executive Summary: The c-Myc tag Peptide is a synthetic peptide corresponding to amino acids 410–419 of human c-Myc, designed for displacement of c-Myc-tagged fusion proteins from anti-c-Myc antibodies in immunoassays (APExBIO). It is soluble at ≥60.17 mg/mL in DMSO and ≥15.7 mg/mL in water (ultrasonic treatment), but insoluble in ethanol (APExBIO, 2024). c-Myc is a proto-oncogene transcription factor that regulates proliferation, growth, apoptosis, and differentiation (Wu et al., 2021). The peptide specifically blocks anti-c-Myc antibody binding, enabling precise immunoassay controls (EpitopePeptide). This reagent is for research use only and not for diagnostic or clinical applications (APExBIO).

Biological Rationale

The c-Myc protein is a fundamental regulator of cell biology, encoded by the MYC proto-oncogene on human chromosome 8q24.21. It functions as a transcription factor, controlling gene networks involved in cell cycle progression, metabolism, differentiation, stem cell self-renewal, apoptosis, and cellular transformation (Wu et al., 2021). c-Myc regulates genes such as cyclins, ribosomal proteins, p21, and Bcl-2, orchestrating both proliferative and apoptotic pathways. Aberrant c-Myc activity is implicated in tumorigenesis and is frequently observed in various cancers, including Burkitt lymphoma and breast carcinoma. Targeting c-Myc and its associated pathways is a major focus in cancer biology and therapeutic research.

Mechanism of Action of c-Myc tag Peptide

The c-Myc tag Peptide (A6003) is a synthetic decapeptide (sequence: EQKLISEEDL) corresponding to the C-terminal residues 410–419 of the human c-Myc protein. In immunoassays, this peptide competitively binds to anti-c-Myc monoclonal antibodies, displacing c-Myc-tagged fusion proteins from antibody complexes (AmericaPeptides). This mechanism enables quantification of specific antibody-peptide interactions and serves as a competitive inhibitor in immunoprecipitation or Western blot workflows. The peptide’s specificity for the anti-c-Myc antibody ensures minimal off-target effects and reliable displacement dynamics. Its solubility profile (≥60.17 mg/mL in DMSO, ≥15.7 mg/mL in water with ultrasonic treatment) allows high-concentration assay setups, while ethanol insolubility prevents interference in alcohol-based protocols (APExBIO).

Evidence & Benchmarks

• The c-Myc tag Peptide (EQKLISEEDL) effectively displaces c-Myc-tagged fusion proteins from anti-c-Myc antibodies in both immunoprecipitation and ELISA formats (Wu et al., 2021).
• c-Myc is a central transcription factor for cell proliferation, and its dysregulation is linked to cancer pathogenesis (Wu et al., 2021).
• The c-Myc tag Peptide is stable when stored desiccated at -20°C but loses activity with prolonged solution storage (>1 week, room temperature) (APExBIO).
• Solubility is quantified at ≥60.17 mg/mL in DMSO and ≥15.7 mg/mL in water following ultrasonic treatment, facilitating high-sensitivity immunoassays (APExBIO).
• Competitive inhibition is dose-dependent and saturable at high peptide:antibody ratios, allowing titration for protocol optimization (EpitopePeptide).

This article extends prior analyses (e.g., AmericaPeptides) by providing updated quantitative solubility benchmarks and clarifying storage stability, which are crucial for reproducible immunoassay outcomes.

Applications, Limits & Misconceptions

The c-Myc tag Peptide is used in:

• Displacement assays to evaluate the specificity and affinity of anti-c-Myc antibodies.
• Western blot and immunoprecipitation workflows to elute c-Myc-tagged proteins from antibody complexes.
• Competitive binding studies in cancer biology, elucidating c-Myc-mediated gene regulation and amplification (ABT888).

Common Pitfalls or Misconceptions

• The c-Myc tag Peptide does not inhibit the functional activity of endogenous c-Myc protein in live cells; it only displaces tagged proteins in vitro.
• It is ineffective in ethanol-based buffers due to insolubility, leading to precipitation and assay failure.
• The peptide is not designed for diagnostic or therapeutic use; it is for research applications only (APExBIO).
• Prolonged storage of peptide solutions at room temperature results in degradation and loss of activity; always store desiccated at -20°C for maximum stability.
• Cross-reactivity with non-c-Myc antibodies is negligible, but confirm specificity with appropriate negative controls.

Compared to guides like GDC0449, which focus on immunoassay protocols, this article emphasizes physicochemical parameters vital for reproducibility and high-throughput assay design.

Workflow Integration & Parameters

For optimal use, the c-Myc tag Peptide should be reconstituted in DMSO or water (with ultrasonic agitation) to achieve the recommended working concentration. Typical protocols involve adding the peptide to antibody-bound matrices to competitively elute c-Myc-tagged proteins. Key parameters:

• Solubility: Dissolve in DMSO (≥60.17 mg/mL) or water (≥15.7 mg/mL, ultrasonicated) for stock solutions.
• Storage: Store lyophilized peptide desiccated at -20°C. Avoid freeze-thaw cycles and long-term storage of reconstituted solutions.
• Assay Design: Titrate peptide concentration based on antibody and target protein abundance. Confirm displacement by Western blot or ELISA readout.
• Controls: Include negative controls (no peptide or irrelevant peptide) and positive controls (known c-Myc-tagged protein).

For a broader methodological context, see Ibupr.com, which discusses novel mechanistic insights. This article updates those findings by detailing solubility and storage constraints critical for modern lab workflows.

Conclusion & Outlook

The c-Myc tag Peptide (A6003, APExBIO) is a validated, highly specific reagent for anti-c-Myc antibody displacement in immunoassays. It enables precise measurement of antibody binding, supports research into c-Myc-mediated transcriptional regulation, and is indispensable for studies of proto-oncogene function in cancer biology. Strict adherence to solubility and storage conditions maximizes its utility and reproducibility. As research advances, integration of this peptide into multiplexed and high-throughput assays is expected to further elucidate c-Myc’s role in oncogenesis and therapeutic targeting (Wu et al., 2021).